IP Library Granted Patent US 9,404,086
Granted Patent B2
US 9,404,086 · App. 14/225,740 · Granted Aug 2, 2016

Method for cell differentiation

Inventor: Katarzyna Anna Czysz (London, GB)
Assignee: GE HEALTHCARE UK LIMITED
C12N5/0672C12N5/067G01N33/502G01N33/5014G01N33/5067C12N2500/62C12N2501/119C12N2501/12C12N2501/155C12N2501/16C12N2501/237C12N2501/33C12N2501/39C12N2506/02G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,404,086
App. No.
14/225,740
Granted
Aug 2, 2016
Kind
B2
Abstract

The present invention relates to the field of cell biology, in particular to methods for differentiating pluripotent stem cells. The invention provides methods for differentiating primate pluripotent stem cells into cells of all three germinal layers. In particular, methods for differentiating primate pluripotent stem cells into the definitive endoderm are provided.

Claims (12)

1. A method for producing definitive endoderm (DE) cells from primate pluripotent stem cells (pPSC) comprising culturing the pPSC in a medium comprising Activin A and a dimethyl sulfoxide (DMSO), thereby producing DE cells that express a gene selected from the group consisting of SOX17, CXCR4 and GATA4.

2. The method of claim 1 , wherein said Activin A is present in said medium at a concentration in a range from 50 ng/ml to 150 ng/ml.

3. The method of claim 2 , wherein the Activin A is present in the medium at a concentration of 100 ng/ml.

4. The method of claim 1 , wherein said pPSC are cultured in the presence of varying concentrations of said DMSO.

5. The method of claim 4 , wherein said DMSO is present in the medium at a concentration in a range from 0.25% to 2% volume/volume.

6. The method of claim 5 , wherein the DMSO is present in the medium at a concentration in the range from 0.25% to 0.75% volume/volume.

7. The method of claim 6 , wherein the DMSO is present in the medium at a concentration in the range from 0.5% to 0.6% volume/volume.

8. The method of claim 4 , wherein the pPSC are initially cultured in the presence of a high concentration of DMSO and then cultured in the presence of a low concentration of DMSO.

9. The method of claim 1 , wherein the medium additionally comprises one or more growth factors or modulators selected from the group consisting of FGF2, Wnt3a, SFRP5 and LY294002.

10. The method of claim 1 , wherein the pPSC are cultured in the medium for 3 to 5 days.

11. The method of claim 10 , wherein the pPSC are cultured in the medium for 4 days.

12. The method of claim 1 , wherein the pPSC are selected from the group consisting of human embryonic stem cells or human induced pluripotent stem cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2020
From: GE HEALTHCARE UK LIMITED
To: GLOBAL LIFE SCIENCES SOLUTIONS OPERATIONS UK LTD
Reel/Frame 053653/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2014
From: CZYSZ, KATARZYNA ANNA
To: GE HEALTHCARE UK LIMITED
Reel/Frame 032593/0988 →
Continuity (1)
Related Publication 20150275178A1 · Oct 1, 2015